Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis Journal Article


Authors: Wu, K. D.; Zhou, L.; Burtrum, D.; Ludwig, D. L.; Moore, M. A. S.
Article Title: Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis
Abstract: Although many multiple myeloma (MM) patients initially respond to cytotoxic therapy, most eventually relapse. Novel therapeutic strategies employing a combination of chemotherapy with targeted biologics may significantly enhance the response of tumor cells to treatment. We tested a fully human anti-IGF-IR antibody (A12) against MM, and showed specific inhibition of IGF-I or serum -induced IGF-IR signaling in MM cells in vitro. The A12 as a single agent was demonstrated to exert modest to significant inhibition of tumor growth in vivo in various subcutaneous xenograft MM models. The A12 was also evaluated in a disseminated xenograft MM.1S NOD/SCID model as monotherapy or in combination with other drugs (bortezomib, melphalan) currently in clinical use. The tumor burden, as determined by luciferase bioimaging, was sharply decreased, and overall survival significantly prolonged when the therapies were combined. Immunohistochemical analysis demonstrated that the A12 treated tumors had significantly decreased vascularization compared to control tumors. Furthermore, most MM lines constitutively secreted significant quantities of VEGF, and this was enhanced following IGF-I treatment. Inhibition of IGF-IR by the A12 in vitro suppressed both constitutive and IGF-I-induced secretion of VEGF, indicating that a putative anti-angiogenic mechanism associated with the A12 treatment may contribute to its anti-tumor effect. © 2006 Springer-Verlag.
Keywords: immunohistochemistry; survival; vasculotropin; cancer chemotherapy; controlled study; survival rate; unclassified drug; human cell; monotherapy; nonhuman; antineoplastic agents; cell proliferation; animals; mice; cell survival; bortezomib; multiple myeloma; boronic acids; pyrazines; antineoplastic combined chemotherapy protocols; animal model; immunoglobulin; melphalan; antineoplastic activity; mice, scid; xenograft model antitumor assays; cell line, tumor; structure-activity relationship; angiogenesis; neovascularization, pathologic; vascularization; somatomedin c receptor; receptor, igf type 1; cancer inhibition; antibodies, monoclonal; xenograft; receptor tyrosine kinase; imaging; targeted therapy; somatomedin c; disease models, animal; mice, inbred nod; injections, subcutaneous; antiangiogenic activity; antibody; combined immunodeficiency; anti-angiogenesis; injections, intravenous; somatomedin c receptor antibody; human antibody; igf-ir
Journal Title: Cancer Immunology, Immunotherapy
Volume: 56
Issue: 3
ISSN: 0340-7004
Publisher: Springer  
Date Published: 2007-03-01
Start Page: 343
End Page: 357
Language: English
DOI: 10.1007/s00262-006-0196-9
PUBMED: 16832681
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 23" - "Export Date: 17 November 2011" - "CODEN: CIIMD" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Kaida Wu
    29 Wu
  2. Li Zhou
    3 Zhou
  3. Malcolm A S Moore
    483 Moore